Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

Weight gain and other metabolic side effects of bipolar and schizophrenia drugs may be countered

A new study suggests that young people who are diagnosed with bipolar disorder and schizophrenia may be spared the side-effects of taking medication with the right diet and exercise program.

11 Jan 2012

Occasional marijuana use does not affect lung function: Study

A new study published in the Journal of the American Medical Association has shown that an occasional drag on marijuana does not appear to have long-term adverse effects on lung function.

11 Jan 2012

Study: Younger the age at migration, higher the risk of psychotic disorders

Recent research has found striking links between psychotic disorders such as schizophrenia and certain types of international immigration. Now for the first time, a major study has found that immigrating in early childhood appears to carry the highest risk.

6 Jan 2012

Adolescents diagnosed with schizophrenia appear to show greater brain GM volume loss

Adolescents diagnosed with schizophrenia and other psychoses appear to show greater decreases in gray matter volume and increases in cerebrospinal fluid in the frontal lobe compared to healthy adolescents without a diagnosis of psychosis, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Jan 2012

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.

5 Dec 2011

Study looks at effects of antipsychotic drugs on two brain receptors linked to schizophrenia

Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.

24 Nov 2011

Drug abuse high in West Australian young men: Study

According to a drug expert almost one in 10 men under 30 years of age has regularly used stimulant drugs and West Australians are the worst offenders.

21 Nov 2011

ACADIA third quarter revenues decrease to $584,000

9 Nov 2011

Link between heavy methamphetamine use and schizophrenia

In the first worldwide study of its kind, scientists from Toronto's Centre for Addiction and Mental Health (CAMH) found evidence that heavy methamphetamine users might have a higher risk of developing schizophrenia.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Children with polyarticular JIA benefit from early and aggressive therapy

Children with juvenile arthritis who are treated early and aggressively have better outcomes, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Affective symptoms can help diagnose early psychotic disorders

Functional psychosis can be diagnosed from the first indications of the patient, thanks to affective symptomatology. Depressive moods, hyperactivity and lack of concentration are affective symptoms that can present themselves during the first psychotic episodes, and the presence or absence of any of them may contribute to differentiating, at an early stage, between the different variations of the mental disease.

3 Nov 2011

Study: People with schizophrenia have weakened sense of body ownership

A study using a procedure called the rubber hand illusion has found striking new evidence that people experiencing schizophrenia have a weakened sense of body ownership and has produced the first case of a spontaneous, out-of-body experience in the laboratory.

1 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

National award encourages bio-science student researchers

A key challenge for the bio-sciences sector is to keep its best research graduates in science and in Australia. The national student awards recognise and encourage promising research students and raise awareness of biosciences research translation and applications.

17 Oct 2011

Cannabis use leads to increased risk of depression in young people with specific genotype

Young people who are genetically vulnerable to depression should be extra careful about using cannabis: smoking cannabis leads to an increased risk of developing depressive symptoms.

10 Oct 2011

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca today announced it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Handa Pharmaceuticals, LLC regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR extended-release tablets.

30 Sep 2011

Benefits and harms vary among atypical antipsychotics for off-label use

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA.

28 Sep 2011

Researchers confirm strong bidirectional relation between epilepsy, schizophrenia

Researchers from Taiwan have confirmed a bidirectional relation between schizophrenia and epilepsy. The study published today in Epilepsia, a journal of the International League Against Epilepsy (ILAE), reports that patients with epilepsy were nearly 8 times more likely to develop schizophrenia and those with schizophrenia were close to 6 times more likely to develop epilepsy.

19 Sep 2011

First-ever comprehensive study of species origins of nature-derived drugs

In a first-ever comprehensive study of the species origins of nature-derived drugs, it is shown that drug-producing species are concentrated and clustered in a limited number of families, refuting the conventional view that as every nature species produces biologically active molecules, one can find drugs from almost any major block of species groups if one looks for them hard enough.

8 Sep 2011